摘要
DAF方案治疗原发性肝癌12例,有效率(MR)为5/12(41.67％),稳定率(MR+s)为8/12(66.67％),恶化率为4/12(33.33％)。平均生存期为9个月,中数生存期为5个月。一年生存率为3/12(25.00％)。该方案毒性低,患者可以耐受。
From Jun. 1985 to Dec. 1987, 12 patients with primary hepatocellular carcinoma were treated with DDP (D) ADM (A) , 5-Fu (F) and rubdosia. The response rate (MR) was 5/12 (41.76％). The stable rate was 8/12 (66.67％). The progressive rate was 4/12 (33.33％). The average survival duration was 9 months. The medium survival duration was 5 months. The one year survival rate was 25.00％. The toxity of DAI regimen was low and receptible.
出处
《河南肿瘤学杂志》
1991年第3期36-37,共2页
Henan Journal of Oncology
关键词
肝癌
chemotherapy
primary hepatocellular carcinoma
survival duration
